Gocovri (Amantadine)

Dyskinesia (Parkinson's disease)

Quarterly Sales (Approved)

Exp Date

February 26, 2021 (Est)

Amp Volatility Score


Catalyst Info & Data Links


  • The mechanism by which GOCOVRI® exerts efficacy in the treatment of dyskinesia in patients with PD is unknown

  • GOCOVRI® (amantadine) extended-release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also the only medicine clinically proven to reduce both dyskinesia and OFF. Taken once daily at bedtime, GOCOVRI provides an initial lag and a slow rise in amantadine concentration during the night, resulting in a high concentration from the morning and throughout the waking day. Additionally, in the clinical trials, the adjunctive use of GOCOVRI did not require dose changes to dopaminergic therapies. The most commonly observed adverse reactions with GOCOVRI were hallucinations, dizziness, dry mouth, peripheral edema, constipation, falls, and orthostatic hypotension. For more information about GOCOVRI, please visit

Updated by MV

#Parkinsonsdisease #ADMS #Gocovri #dyskinesia #Amantadine #autoimmunedisease

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See What The Community Is Saying - Click To See Full Post

ADMS - Adamas Reports Third Qu...

Summary: Third quarter 2020 total revenues of $20.2 million, a 45% increase over third quarter 2019 Third quarter 2020 GOCOVRI® product sales of $19.0 million, a 36% increase over third quarter 2019 T...

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon